

1 This article was published in Biofouling, 32(3), 227-241, 2016

2 <http://dx.doi.org/10.1080/08927014.2015.1124096>

3

4 **Impact of *Delftia tsuruhatensis* and *Achromobacter xylosoxidans* on**  
5 ***Escherichia coli* dual-species biofilms treated with antibiotic agents**

6

7 Andreia S. Azevedo<sup>1,2</sup>, Carina Almeida<sup>1,3</sup>, Bruno Pereira<sup>1</sup>, Luís F. Melo<sup>1</sup>, Nuno F. Azevedo<sup>1,\*</sup>

8 <sup>1</sup>Laboratory for Process Engineering, Environment, and Energy and Biotechnology Engineering  
9 (LEPABE), Department of Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr  
10 Roberto Frias, 4200-465 Porto, Portugal;

11 <sup>2</sup>Nucleic Acid Center, Department of Physics, Chemistry and Pharmacy, University of Southern Denmark,  
12 5230 Odense M, Denmark;

13 <sup>3</sup>Institute for Biotechnology and Bioengineering (IBB), Centre of Biological Engineering, Universidade do  
14 Minho, Campus de Gualtar, 4710-057 Braga, Portugal<sup>c</sup>

15

16 Andreia S. Azevedo - [deq11016@fe.up.pt](mailto:deq11016@fe.up.pt)

17 Carina Almeida - [carinaalmeida@deb.uminho.pt](mailto:carinaalmeida@deb.uminho.pt)

18 Bruno Pereira - [bfpereira@ua.pt](mailto:bfpereira@ua.pt)

19 Luís F. Melo - [lmelo@fe.up.pt](mailto:lmelo@fe.up.pt)

20 \*Corresponding author. E-mail: [nazevedo@fe.up.pt](mailto:nazevedo@fe.up.pt); Phone number: +351 22 508 158; Fax number: +351  
21 22 508 1449

22

23

24 \*Address correspondence to Nuno F. Azevedo, [nazevedo@fe.up.pt](mailto:nazevedo@fe.up.pt)

25

26

27

28 **Abstract**

29 Recently it was demonstrated that for urinary tract infections species with a lower or unproven  
30 pathogenic potential such as *Delftia tsuruhatensis* and *Achromobacter xylosoxidans*, might  
31 interact with conventional pathogenic agents as such *Escherichia coli*. In here, single- and dual-  
32 species biofilms of these microorganisms were characterized in terms of microbial composition  
33 over time, average fitness of *E. coli*, spatial organization and biofilm antimicrobial profile. Results  
34 revealed a positive impact of these species on *E. coli* fitness and a greater tolerance to the  
35 antibiotic agents. Surprisingly, in dual-species biofilms exposed to antibiotics, *E. coli* was able to  
36 dominate the microbial consortia in spite of being the most sensitive strain. This is the first study  
37 demonstrating the protective effect of less common species over *E. coli* under adverse conditions  
38 imposed by the use of antibiotic agents.

39

40 **Keywords:** multispecies biofilms, catheter-associated urinary tract infections, antibiotics,  
41 *Escherichia coli*, uncommon species, LNA/2'OMe-FISH.

42

43

## 44 **Introduction**

45

46 Healthcare-associated infections include the urinary tract infections (UTIs) (Kline et al. 2012),  
47 cystic fibrosis lung disease (Baldan et al. 2014), and device-related infections (Armbruster et al.  
48 2014, Frank et al. 2009, Hola et al. 2010, Stickler 2008) (e.g. urinary catheters). Concerning the  
49 catheter-associated urinary tract infections (CAUTIs), *Escherichia coli* is typically one of the  
50 most prevailing bacteria (Niveditha et al. 2012, Ronald 2002). Advances in molecular  
51 technologies have disclosed that in short-term catheterization, the surface of the urinary catheter  
52 is frequently colonized by a single species; while, in the long-term catheterization, a diverse  
53 microbial community inhabiting the urinary catheter surface can be observed, with a  
54 predominance of gram-negative bacteria (Hola et al. 2010, Hooton et al. 2010, Nicolle 2005).  
55 Nonetheless, only a few studies have examined mixed-species structures (eg Azevedo et al. 2014,  
56 Cerqueira et al. 2013), and hence, our current knowledge about interspecies dynamic within  
57 polymicrobial biofilms, such as microbe-microbe interactions, remains scarce (Elias & Banin  
58 2012).

59 Two of the species less commonly found on the surface of urinary catheters are *Delftia*  
60 *tsuruhatensis* and *Achromobacter xylosoxidans* (Frank et al. 2009). These species have been  
61 shown to be able to coexist with *E. coli* in biofilms, and a pre-colonization of the surface with  
62 these species seemed to promote *E. coli* adhesion (Azevedo et al. 2014). While only a limited  
63 number of studies have investigated the behavior and role of *E. coli* in catheters-associated  
64 polymicrobial biofilms (eg Azevedo et al. 2014, Cerqueira et al. 2013, Spadafino et al. 2014), a  
65 previous study has suggested that uncommon bacteria interact synergistically with this pathogen  
66 (Azevedo et al. 2014). Similar results were reported for cystic fibrosis associated species, where  
67 two other uncommon bacteria, *Inquilinus limosus* and *Dolosigranulum pigrum*, were able to  
68 interact synergistically with *Pseudomonas aeruginosa* (Lopes et al. 2012). This type of interaction  
69 also resulted into an increased tolerance of the overall consortia to a wide range of antibiotics.  
70 Although the pathogenic nature of these uncommon bacteria remains unknown, these studies  
71 suggest that some species might cooperate with conventional microorganisms (e.g. *E. coli*, *P.*  
72 *aeruginosa*) to form mixed biofilms in order to protect them from environmentally challenging  
73 condition such as antibiotic exposure.

74 The present study aimed to assess the effect that the uncommon species might have on  
75 the fitness and antimicrobial profile of *E. coli* biofilms. *E. coli* and two less common species, *D.*  
76 *tsuruhatensis* and *A. xylosoxidans*, were used to form single- and dual-species biofilms on silicone  
77 surfaces. Then, the single- and dual-species biofilms were characterized in terms of microbial

78 composition over time, average fitness of *E. coli*, spatial organization and biofilm antimicrobial  
79 profile.

80 The interactions, synergetic or antagonistic, among the species within the biofilm have  
81 been demonstrated to have a crucial role in the process of biofilm development, architecture and  
82 resistance to several antimicrobial agents (Burmolle et al. 2006, Kostaki et al. 2012, Leriche et al.  
83 2003, Simoes et al. 2009). This information might then provide data to model microbial behavior  
84 on polymicrobial communities and might also be the base for new personalized treatment  
85 strategies (Lopes et al. 2015).

86

87

## 88 **Materials and methods**

89

### 90 ***Culture conditions and preparation of inocula***

91 For each experiment, *E. coli* CECT 434, *A. xylosoxidans* B3 and *D. tsuruhatensis* BM90 were  
92 streaked from a frozen stock (-80°C) on Tryptic Soy Agar (TSA) (Merk, Germany) and grown  
93 overnight at 37°C. *E. coli* CECT 434 was originally isolated from a clinical sample in Seattle,  
94 Washington, and is often used in quality control testing; *A. xylosoxidans* B3 was isolated from  
95 sewage sludge (Reinecke et al. 2000); *D. tsuruhatensis* BM90 was previously isolated from water  
96 samples collected at 90 m deep in the Tyrrhenian Sea off the coast of Giglio Island, Grosseto,  
97 Italy (Fenice et al. 2007).

98 For the preparation of the inocula, cells were subcultured (16-18 hours) at 37°C and 150  
99 rpm, in artificial urine medium (AUM). AUM was prepared as previously described (Brooks &  
100 Keevil 1997). Cell concentration was assessed by optical density at 620 nm (O.D.<sub>620 nm</sub>), and the  
101 inoculum was diluted in AUM in order to obtain a final concentration of 10<sup>5</sup> CFUs ml<sup>-1</sup>.

102

### 103 ***Single- and dual-species biofilm formation***

104 Single-species biofilms were formed to study the biofilm-forming ability of each species on  
105 silicone material, which is frequently used in urinary catheters (Lawrence & Turner 2005, Stickler  
106 2008). In order to understand the interactions that occur between *E. coli* and the less common  
107 microorganisms, 2 species combinations (*E. coli* 10<sup>5</sup> CFU ml<sup>-1</sup>/ *D. tsuruhatensis* 10<sup>5</sup> CFU ml<sup>-1</sup>;  
108 *E. coli* 10<sup>5</sup> CFU ml<sup>-1</sup>/ *A. xylosoxidans* 10<sup>5</sup> CFU ml<sup>-1</sup>) were studied.

109 Coupons of silicone (Neves & Neves Lda, Portugal) were cut (dimensions of 2 × 2 cm or  
110 1 × 1 cm), cleaned and sterilized according to the procedure described by Azevedo et al. (2006).  
111 Each coupon of silicone was placed in the bottom of the wells of the 6-well tissue culture plates  
112 (Orange Scientific, Braine-l'Alleud, Belgium).

113 Cell suspension cultures prepared in AUM at 10<sup>5</sup> CFUs ml<sup>-1</sup> were used as an inoculum  
114 for biofilm formation. Single- and dual-species biofilms were formed as previously described

115 (Azevedo et al. 2014). Two independent experiments were performed for each condition. At  
116 specific times (2, 4, 6, 24, 48, 96 and 192 h), the biofilm formation was assessed by CFU counts.  
117 The spatial organization of dual-species biofilm was also performed using LNA/2'OMe-FISH at  
118 192 h.

119

### 120 ***CFU counts for quantification of biofilm cells***

121 At each time point the silicone coupons with biofilm were washed three times in 10 ml of 0.85%  
122 (v/v) sterile saline solution to remove loosely attached cells. After washing, coupons were placed  
123 in a new well of the tissue plate containing 9 ml of sterile saline solution 0.85% (v/v);  
124 subsequently, the biofilms were sonicated (Sonopuls HD 2070, Bandelin Electronics, Germany)  
125 for 10 seconds with 25 % amplitude. The sonication conditions were previously optimized to  
126 guarantee that the cells were detached from the silicone coupons, avoiding the bacteria lysis (data  
127 not shown). Afterwards, the CFU counts were performed. For this, 100  $\mu$ l of the disrupted biofilm  
128 were serially diluted (1:10) in saline solution, and plated in triplicate on TSA (for the single-  
129 species biofilms). The plates were incubated at 37°C for 12–16 h (*E. coli*), 24 h (*D. tsuruhatensis*)  
130 and 48 h (*A. xylosoxidans*). For discrimination of the species involved on the dual-species  
131 biofilms, different selective agar media were used, as described on Azevedo et al. (2014).  
132 MacConkey agar (Liofilchem) was used to assess the *E. coli* CFU counts; and, for assessing the  
133 *A. xylosoxidans* and *D. tsuruhatensis* counts the Cetrimide agar (Liofilchem) and Simmons Citrate  
134 agar (ammonium dihydrogen phosphate 1 g l<sup>-1</sup> [Merck]; di-potassium hydrogen phosphate 1 g l<sup>-1</sup>  
135 [Merck]; sodium chloride 5 g l<sup>-1</sup> [Merck]; tri-sodium citrate 2 g l<sup>-1</sup> [Sigma, StLouis, MO, USA];  
136 magnesium sulfate 0.2 g l<sup>-1</sup> [Merck]; bromothymol blue 0.08 g l<sup>-1</sup> [Sigma]; agar 13 g l<sup>-1</sup> [Merck])  
137 were used, respectively. Subsequently, the selective agar plates were incubated at 37°C for 12–  
138 16 h (*E. coli*), 48 h (*A. xylosoxidans*) and 72 h (*D. tsuruhatensis*). The number of CFU in biofilms  
139 was determined and expressed per unit area of silicone coupon in contact with AUM (Log CFUs  
140 cm<sup>-2</sup>). These values were used for the determination of the *E. coli* fitness relative to the less  
141 common species ( $W_{E. coli}$ ) as previously described by Azevedo et al. (2014).

142 Briefly, the  $W_{E. coli}$  was estimated as the ratio of the malthusian parameters (m) of each  
143 species (Lenski et al. 1991). This parameter is defined as the average rate of increase and was  
144 calculated for both species over the time,

145

$$146 \quad m = \ln [N (t_{\text{final}}) / N (t_{\text{initial}})] / t_{\text{final}} \quad (1)$$

147

148 where N is the value of CFU cm<sup>-2</sup> present in the biofilm at initial time ( $t_{\text{initial}}$ ) and final time ( $t_{\text{final}}$ )  
149 points. Then, the  $W_{E. coli}$  was determined as,

150

$$151 \quad W_{E. coli} = m_{E. coli} / m_{\text{uncommon species}} \quad (2)$$

152

153 The value of  $W_{E. coli}$  indicates the influence of the less common species on the *E. coli* behaviour  
154 when co-cultured; a fitness of 1 means that the species are equally fit.

155

#### 156 ***Antibiotic stock solutions***

157 Four relevant antibiotics commonly used in the treatment of UTIs and CAUTIs (Dellimore et al.  
158 2013, Hooton et al. 2010, Steinman et al. 2003, Zhanel et al. 2000), with distinct modes of action,  
159 were selected, namely: ciprofloxacin (Sigma-Aldrich, Portugal), ampicillin (AppliChem,  
160 Germany), gentamicin (AppliChem, Germany), amoxicillin/clavulanic acid (Sigma-Aldrich,  
161 Portugal). Stock solution of antibiotics were prepared at 100 000 mg/l. Working solutions were  
162 prepared on the day of use at 1024 mg/l, and from these two-fold serial dilutions were made in  
163 AUM. The antibiotic concentrations tested ranged from 0.5 to 1024 mg l<sup>-1</sup>.

164

#### 165 ***Antibiotic susceptibility testing***

166 The antibiotic susceptibility of single- and dual-species biofilms pre-formed on silicone coupons  
167 was evaluated according to Ceri et al. (1999) with slight modifications. Briefly, silicone coupons  
168 (1 × 1 cm) were placed on the bottom of the wells of the 24-well tissue culture plates (Orange  
169 Scientific, Braine-l'Alleud, Belgium). The biofilm formation was performed as described above.  
170 After 48 h, silicone coupons with biofilm were washed three times in 3 ml of 0.85% (v/v) sterile  
171 saline and placed in a new well of the tissue culture plate. Then, two-fold serial dilutions of the  
172 antibiotic in AUM were applied in the pre-established biofilms and the plates were incubated for  
173 24 h at 37°C, under static conditions. It is important to notice that, at 48 h, the biofilms are mature  
174 and the species involved in dual-species biofilms are equally fit.

175 After the antibiotic exposure, the coupons with biofilms were washed and placed in a new  
176 well of the 24-well tissue culture plate containing 1.5 ml of 0.85% (v/v) sterile saline.  
177 Subsequently, biofilms were sonicated, as described above, and the suspension of each biofilm  
178 was spotted onto TSA plates. The plates were incubated at 37°C for CFU enumeration. These  
179 counts allowed to determine the minimum biofilm eradication concentration (MBEC) values,  
180 which corresponded to the lower concentration of antibiotic required to eradicate 99% of the  
181 sessile bacteria.

182

#### 183 ***Determination of the species relative composition after antibiotic exposure***

184 To determine the effect of sub-MBEC concentrations of antibiotics on the species composition in  
185 the dual-species biofilms, the CFU enumeration was performed for the concentration close to the  
186 MBEC and 8× and 64× lower concentrations. Then, population compositions after and before  
187 antibiotic exposure, were compared. A previous study showed a good correlation between

188 LNA/2'OMe-FISH procedure and CFU counts (Azevedo et al. 2015); therefore, it was considered  
189 that the CFU enumeration reflects the population involved in the dual-species biofilms.

190

### 191 ***Effect of inoculum size on the species relative composition after antibiotic exposure***

192 To understand the effect of inoculum size on the species relative composition in antibiotic treated  
193 dual-species biofilms, two conditions were tested: i) the antibiotic susceptibility of *E. coli* 10<sup>5</sup>  
194 CFU ml<sup>-1</sup>/ *D. tsuruhatensis* 10<sup>2</sup> CFU ml<sup>-1</sup> and *E. coli* 10<sup>5</sup> CFU ml<sup>-1</sup>/ *A. xylosoxidans* 10<sup>2</sup> CFU  
195 ml<sup>-1</sup> dual-species biofilms to four antibiotic agents; ii) the susceptibility to ampicillin and  
196 amoxicillin/clavulanic acid was tested for the *E. coli* 10<sup>2</sup> CFU ml<sup>-1</sup>/ *D. tsuruhatensis* 10<sup>5</sup> CFU  
197 ml<sup>-1</sup> and *E. coli* 10<sup>2</sup> CFU ml<sup>-1</sup>/ *A. xylosoxidans* 10<sup>5</sup> CFU ml<sup>-1</sup> dual-species biofilms. These  
198 experiments were performed as described above. The CFU enumeration was also performed for  
199 the concentration close to the MBEC and 8× and 64× lower concentrations to determine the  
200 species relative composition of each dual-species biofilm.

201

### 202 ***Spatial organization of biofilm populations***

203 In order to assess the biofilm spatial organization and the species distribution, the LNA/2'OMe-  
204 FISH procedure in combination with confocal laser scanning microscopy (CLSM) analysis was  
205 performed directly on dual-species biofilms formed on silicone coupons at 192 h and on  
206 ampicillin treated-biofilms, according to a protocol already developed by Azevedo et al. (2015).  
207 Briefly, coupons were washed in 0.85% (v/v) sterile saline; to prevent the detachment of biofilm  
208 during hybridization, the biofilms were dried at ~60°C for 15 min and fixed with 100% methanol  
209 for 20 min. Afterwards, for the fixation step, the biofilms coupons were immersed in 4% (v/v)  
210 paraformaldehyde and 50% (vol/vol) ethanol, for 15 min each at room temperature, and allowed  
211 to air dry. Subsequently, a hybridization buffer (0.5 M of urea [VWR BHD Prolabo.], 50 mM  
212 Tris-HCl [Fisher Scientific], 0.9 M NaCl [Panreac]; pH 7.5) with 200 nM of the respective probe,  
213 were added. The samples were covered with coverslips and incubated in moist chambers at 57°C  
214 during 90 min. Next, the coverslips were removed and the coupons were washed in a pre-warmed  
215 washing solution (5 mM Tris Base [Fisher Scientific], 15 mM NaCl [Panreac] and 1% Triton X  
216 [Panreac]; pH 10) for 30 min at the same temperature of the hybridization step. Finally, the  
217 coupons were allowed to air dry before CSLM visualization. The biofilm CSLM images were  
218 acquired in a FluoViewFV1000 microscope (Olympus). Biofilm was observed using a 60×water-  
219 immersion objective (60×/1.2W). Multichannel simulated fluorescence projection images and  
220 vertical cross sections through the biofilm were generated by using the FluoView application  
221 Software package (Olympus). *E. coli* cells were identified as green fluorescent bacillus and the  
222 uncommon bacteria as bright red fluorescent bacillus.

223

### 224 ***Statistical analysis***

225 Results were compared using One-Way analysis of variance (ANOVA) by applying Levene's test  
226 of homogeneity of variance and the Tukey multiple-comparisons test, using the SPSS software  
227 (SPSS - Statistical Package for the Social Sciences, Chicago, USA). All tests were performed  
228 with a confidence level of 95%.

229

230

## 231 **Results and discussion**

232

233 Typically, in ecological and clinical environments, biofilm communities are dominated by the  
234 species that is better fitted to the environmental conditions (Jacobsen et al. 2008, Lyczak et al.  
235 2002). However, other pathogenic species, or even, species with an unknown pathogenic potential  
236 (eg *D. tsuruhatensis* and *A. xylosoxidans*) are also present at a lesser extent (Frank et al. 2009).

237 Previous reports on *D. tsuruhatensis* and *A. xylosoxidans* species provided relevant  
238 information about the type of interactions between these species and *E. coli*, as well as on their  
239 impact on biofilm formation and development. While the uncommon species are not directly  
240 involved in the pathogenesis of the biofilm, they seemed to help the establishment of the  
241 predominant species in the microbial consortium (Azevedo et al. 2014, Lopes et al. 2014, Lopes  
242 et al. 2012). As these results were performed in a 96-well plate model, with surfaces that are  
243 composed by polystyrene, the first experiments of the present study intended to clarify if this  
244 behavior is maintained on silicone surfaces. As such, two consortia composed by the *E. coli* and  
245 the less common species (*E. coli*/*D. tsuruhatensis* and *E. coli*/*A. xylosoxidans*), formed on  
246 silicone surfaces, in AUM, at 37°C, were studied.

247

### 248 ***Single- and dual-species biofilms growth and spatial organization of the species on silicone*** 249 ***material***

250 First, we assessed the ability of these species to form biofilm on silicone coupons in single- and  
251 dual-species biofilms. In single-species biofilms, from 2 h up to 48 h, the CFU counts  
252 significantly increased for all species ( $P<0.05$ ). Then, all species stabilized with CFU counts  
253 ranging between Log 7.3 CFUs cm<sup>-2</sup> and Log 7.8 CFUs cm<sup>-2</sup> (data not shown). These results  
254 corroborated the one previously obtained (Azevedo et al. 2014).

255 To study the influence of the less common species on the  $W_{E. coli}$ , *E. coli* was co-cultured  
256 with each of the less common species (Figure 1A). It was clear that at early stages of biofilm  
257 formation the  $W_{E. coli}$  increased significantly in the presence of both less common species  
258 ( $P<0.05$ ). For the *E. coli*/*D. tsuruhatensis* biofilm, this fitness increase was also noticed at 192 h  
259 ( $P<0.05$ ). Overall, these results were similar to the results obtained in polystyrene 96-well tissue  
260 culture plates (Azevedo et al. 2014), where the less common species and *E. coli* coexisted within  
261 the dual-species biofilms at high cell concentrations, with a positive effect on *E. coli* fitness.

262 The elucidation of the species interactions can be supported by the spatial distribution of  
263 the species within the polymicrobial biofilms. It has been shown that particular interactions are  
264 associated with specific spatial organizations (Elias & Banin 2012). As such, a multiplex  
265 LNA/2'OMe-FISH technique previously validated on biofilm samples (Azevedo et al. 2015) was  
266 combined with CLSM to assess the spatial organization of the species in 192 h-dual-species  
267 biofilms (Figure 1-B, C). The information allowed to infer the type of interaction that occurs  
268 between *E. coli* and the less common species. Images show that the dual-species biofilms were  
269 composed by both species mixed together in a typical coaggregation structure. This spatial  
270 organization occurs commonly when the species within the biofilm cooperate or interact  
271 synergistically (Elias & Banin 2012). Relating this information with data described above, it  
272 becomes clear that *E. coli* might benefit from the presence of the *D. tsuruhatensis* and *A.*  
273 *xylosoxidans* or, at least, *E. coli* and these species are not negatively affected by each other's  
274 presence, coexisting in the biofilm.

275 In the synergetic interaction, microorganisms acquire a beneficial phenotype which can  
276 result in the development of a stable biofilm, metabolic cooperation, increased resistance to  
277 antibiotics and host immune responses (Elias & Banin 2012). Several studies have demonstrated  
278 that the polymicrobial consortia are more resistant to antibiotic treatment than the corresponding  
279 mono-species biofilms (Al-Bakri et al. 2005, Burmolle et al. 2006, Kara et al. 2006, Leriche et al.  
280 2003). This demonstrated that under challenging conditions imposed by the use of antibacterial  
281 agents, the species within the biofilm can cooperate metabolically in order to protect themselves  
282 (Elias & Banin 2012, Kara et al. 2006). In fact, the population proportion might be adjusted in  
283 order to reach a new balance better suited to the new environmental conditions.

284

### 285 ***Antibiotic effects on the relative composition and spatial organization of biofilms formed by E.*** 286 ***coli and less common species***

287 Assuming that the less common species might cooperate with *E. coli* and that this cooperation  
288 might have an impact on the antimicrobial profile of the overall microbial consortia, the antibiotic  
289 resistance profiles of dual-species biofilms were characterized. Four relevant antibiotics/antibiotic  
290 combinations with different modes of action were applied in a 48 h pre-established dual-species  
291 biofilms; and, the more prevalent species was determined for the three different antibiotic  
292 concentrations below the MBEC.

293 The antibiotics selected, including ciprofloxacin, gentamicin, ampicillin and  
294 amoxicillin/clavulanic acid (from the fluoroquinolone, aminoglycoside and  $\beta$ -lactam drug-class,  
295 respectively), are widely used in the treatment of UTIs and CAUTIs (Dellimore et al. 2013,  
296 Hooton et al. 2010, Steinman et al. 2003, Zhanel et al. 2000). The MBECs were evaluated for the  
297 single- and dual-species biofilms. Results are listed on Table 1.

298 For the dual-species biofilms (*E. coli* 10<sup>5</sup> CFU ml<sup>-1</sup>/ *D. tsuruhatensis* 10<sup>5</sup> CFU ml<sup>-1</sup>; *E.*  
299 *coli* 10<sup>5</sup> CFU ml<sup>-1</sup>/ *A. xylosoxidans* 10<sup>5</sup> CFU ml<sup>-1</sup>), it was also expected that higher concentrations  
300 of antibiotics were needed to eradicate the consortia than those required to eradicate single-species  
301 biofilms; or, at least, an antibiotic concentration equal to the one needed to eradicate the more  
302 resistant species which, in this case, were *D. tsuruhatensis* and *A. xylosoxidans*. As expected, in  
303 general the MBEC results showed that behavior. An exception was observed for the *E. coli*/ *D.*  
304 *tsuruhatensis* dual-species biofilm where the ciprofloxacin was able to eradicate the biofilm at  
305 very low concentration (0.5 mg l<sup>-1</sup>). While individually the single-species biofilms were highly  
306 resistance to ciprofloxacin; when combined the resulting mixed biofilm was highly susceptible to  
307 the antibiotic. This result reflects how urgent it is to understand the composition and the species  
308 interactions in mixed biofilms in order to select a therapy directed to the species involved.

309 While it was apparent that, in general, the presence of the less common species highly  
310 increased the *E. coli* odds of surviving in the presence of antibiotic agents, it was unclear if the  
311 exposure to these agents results in a new repositioning of the population balance. To further  
312 investigate this, the dual-species biofilm cells were quantified after exposure to antibiotic  
313 concentration near or below the MBEC (the CFU cm<sup>-2</sup> values are present in Supplemental material  
314 on Table S2, S3 and S4). Figure 2 shows which species was more prevalent after the introduction  
315 of specific antibiotic agents. Before antibiotic exposure, the proportions of the species were  
316 similar in both dual-species biofilms with a slight prevalence of *E. coli* (Figure 2-A e B). After  
317 antibiotic exposure, results showed that, in general, the relative bacteria composition of the dual-  
318 species biofilms was dependent of the antibiotic and concentration applied (Figure 2). For  
319 ciprofloxacin, the 3 bacteria presented high MBEC and, thus, the percentages of each population  
320 were more balanced. For the other 3 antibiotics, for which MBEC values of the uncommon species  
321 were much higher than those obtained for the *E. coli*, a different behavior was observed. It would  
322 be expectable that the more resistant species would dominate the microbial consortia. This, in  
323 fact, happened for gentamycin-exposed dual-species biofilms, where the percentage of the  
324 uncommon species increased with the antibiotic concentration. However, the opposite happened  
325 for the ampicillin and amoxicillin/clavulanic acid-exposed biofilms. While the less common  
326 species biofilm cells were much more resistant, surprisingly the *E. coli* population dominated the  
327 consortia. Both ampicillin and amoxicillin/clavulanic acid belong to the same antibiotic class, the  
328  $\beta$ -lactam class, which might explain the similar results obtained for both antibiotics. The  $\beta$ -lactam  
329 antibiotics are able to inhibit the cell wall biosynthesis in the bacterial cell, which ultimately might  
330 lead to the cell lysis (Kohanski et al. 2010). Interestingly, biofilms resistance was observed even  
331 in the presence of clavulanic acid, which is an inhibitor of the  $\beta$ -lactamase production. These  
332 results suggested that a small relative percentage of the *D. tsuruhatensis* and *A. xylosoxidans* was  
333 sufficient to introduce some protective changes on the *E. coli* physiology, promoting its resistance  
334 and survival against the ampicillin and amoxicillin/clavulanic acid treatment. To determine if this

335 protective effect exhibited by *D. tsuruhatensis* and *A. xylosoxidans* is maintained in the presence  
336 of low initial ratios of the species, the initial inoculum concentration of these species was lowered  
337 ( $10^2$  CFU ml<sup>-1</sup>) when co-cultured with *E. coli* ( $10^5$  CFU ml<sup>-1</sup>).

338 In general, while the MBEC values decreased due, in part, to a low initial inoculum  
339 concentration of *D. tsuruhatensis* and *A. xylosoxidans* (Table 2), the *E. coli* population dominated  
340 the consortia after the antibiotic treatment (Figure 3-A, B). The exception was for the  
341 ciprofloxacin action on the *E. coli*  $10^5$  CFU ml<sup>-1</sup>/ *A. xylosoxidans*  $10^2$  CFU ml<sup>-1</sup> (Figure 3-B).  
342 Concerning the gentamycin-treated dual-species biofilms, as previously observed, the results also  
343 showed that the *E. coli* population only survived when the antibiotic concentration was below the  
344 MBEC of *E. coli* single-species biofilms (Figure 3-A, B).

345 Next, it was also important to understand whether the *E. coli* population is able to  
346 dominate the ampicillin and amoxicillin/clavulanic acid treated biofilms even lowering  
347 significantly its initial inoculum concentration ( $10^2$  CFU ml<sup>-1</sup>). The results showed that a lower  
348 initial inoculum concentration of *E. coli* did not affect the MBEC value to ampicillin and  
349 amoxicillin/clavulanic acid of dual-species biofilms (Table S1 in Supplemental material). *E. coli*  
350 lost its dominance when co-cultured with *D. tsuruhatensis*, but in general, was able to persist  
351 within the consortia (~20% of the total population) (Figure 3-A). When co-cultured with *A.*  
352 *xylosoxidans*, *E. coli* maintained its dominance (Figure 3-B).

353 The images captured by CLSM revealed that the dual-species biofilms maintain the same  
354 structure after treatment with ampicillin (Figure 5). The species are closely associated with a  
355 dominance of *E. coli* population (Figure 5-II, VI, VII, VIII). Collectively, these results suggest  
356 that the less common species seems to offer a shared resistance to the *E. coli* population,  
357 independently of its initial inoculum concentration. In fact, Lee et al. have reported that the role  
358 of the species in a consortium is not necessarily related with this abundance; the less abundant  
359 species might have a protective effect over the other members involved in the consortia (Lee et  
360 al. 2014).

361 Recently, several studies have demonstrated a new phenomenon of antibiotic resistance  
362 based on the “shared resistance” by some members of the microbial consortia (Lee et al. 2014,  
363 Perlin et al. 2009, Yurtsev et al. 2013). However, the mechanism underlying this shared resistance  
364 is unknown. For the results presented here, three hypotheses are formulated to explain the  
365 dominance of the more antibiotic-sensitive species in a multispecies biofilm (Figure 6): 1) the  
366 transfer of genetic material from the less common species to *E. coli*; 2) the induction of a different  
367 physiological state in the *E. coli* to the antibiotic uptake; 3) the degradation of the antibiotic on  
368 the biofilm matrix, through the action of the  $\beta$ -lactamases produced by the uncommon species.

369 Horizontal gene transfer of antibiotic resistance genes is a way by which some bacteria  
370 become resistant to antibiotic agents (Broszat & Grohmann 2014). Recent data have also been  
371 provided for the occurrence of this mechanisms in biofilms (Broszat & Grohmann 2014, Ghigo

2001, Hoiby et al. 2010, May et al. 2009, Savage et al. 2013) which may result, in part, from the close cell-to-cell contact occurring in the biofilm (Savage et al. 2013). For instance, the horizontal transfer of specific genes coding for  $\beta$ -lactamases, is not new. May et al. (2009) reported that the resistance to the  $\beta$ -lactam antibiotics is mainly due to the localization of the  $\beta$ -lactamase genes on plasmids, which can spread rapidly among bacteria.

Regarding the induction of a different physiological state, Kara et al. (2006) have suggested this type of interaction for *Streptococcus mutans* and *Veillonella parvula*. When *S. mutans* was co-cultured with *V. parvula*, the latter species induced changes in the gene expression of *S. mutans* allowing its survival under challenging conditions caused by the use of different antibacterial compounds. Another study reported that the sub-inhibitory concentrations of  $\beta$ -lactam antibiotics promotes alterations into the biofilm phenotype, such as a loss of viable bacteria and an increase in biofilm biomass, which can protect and allow the survival of the bacteria exposed to antibiotic agents (Wu et al. 2014).

Regarding the last hypothesis, it was demonstrated that the presence of  $\beta$ -lactamases in the biofilms matrix might inactivate the  $\beta$ -lactam antibiotics (Gould et al. 2008). Lee et al. (2014) suggested that *Pseudomonas protegens* was able to protect all species involved in the microbial consortia (*P. aeruginosa* and *Klebsiella pneumoniae*) when exposed to tobramycin, probably due to the ability of the resistant species to produce enzymes that degrade or modify the antibiotics.

In the present study, as previously reported by Lee et al. (2014), there was no selection of the more resistant species (*D. tsuruhatensis* and *A. xylosoxidans*) over the *E. coli* (the less resistant species). The presence of resistant species, even in low concentration, seemed to offer a protection, allowing the survival and dominance of the *E. coli* within microbial consortia under lethal antibiotic concentrations. While the uncommon species (the resistant species) might have their metabolism directed to the secretion of  $\beta$ -lactamases, *E. coli* (the susceptible cells) might gain benefit from the action of  $\beta$ -lactamases secreted. In this situation, *E. coli* does not expend energy in producing enzymes and may redirect that energy to promote its growth and survival without paying the cost. A similar scenario, described by Foster, reports that the resistant cells, through the production of enzymes that break down the antibiotic agents, promote the growth of susceptible cells without cost, conferring a competitive disadvantage for the resistant cells (Foster 2011).

Finally, it is important to note that to ensure the reproducibility of results the use of an established formula of artificial urine was preferred. In fact, human urine varies significantly in terms of pH and compositions according the type of food intake and the health of the individual (Siener et al. 2004). The formula used in this study was reported as a suitable replacement for normal urine and may be used in a wide range of experiments (eg for modelling the growth and attachment of urinary pathogens in the clinical environment) (Almeida et al. 2013, Azevedo et al. 2014, Brooks & Keevil 1997, Cerqueira et al. 2013, Klinth et al. 2012, Raffi et al. 2012). Also,

409 the use of a dynamic biofilm system might allow to better mimic the urine flow that occurs in the  
410 urinary catheter but the experiments were performed on static conditions using the well plates.  
411 These platforms offer the possibility of providing a larger amount of data (Duetz 2007, Kumar et  
412 al. 2004).

413

414

## 415 **Conclusions**

416 Interactions between *E. coli* and other less common species in CAUTIs can promote *E. coli*  
417 survival under challenging conditions, such as those imposed by the antibiotic agents. A residual  
418 concentration of these less common species appears to be sufficient to protect the *E. coli*  
419 population. In fact, for certain situations where *E. coli* was more sensitive to the antibiotics than  
420 the other microorganisms, it was, nonetheless, able to predominate within the dual-species  
421 biofilms. Combining the results obtained in this work, Figure 6 shows a schematic representation  
422 of the hypothesis proposed in the present work to explain the predominance of a certain species  
423 (*E. coli*, in this case) when a dual-species biofilm is exposed to antibiotics agents or other  
424 molecules.

425 While synergistic interactions between the *E. coli* and the less common species might  
426 significantly contribute to the development of well-organized and resistant biofilm structures, it  
427 also became clear that some particular species-combination might induce metabolic processes  
428 that decrease the resistance mechanism.

429 In conclusion, this study suggested that there are new aspects about the role of uncommon  
430 species that should be investigated such as, how the protection offered by these species contribute  
431 to the survival and dominance of sensitive species under lethal antibiotic concentrations. More  
432 experiments involving this type of species, and understanding the mechanisms involved in  
433 evolution of antibiotic resistance should be taken into consideration. In addition, we suggest that  
434 the microbial composition and environmental conditions present in the polymicrobial biofilms  
435 should be considered on the development and validation of novel antimicrobial strategies.

436

437

## 438 **Acknowledgments**

439 This work was financially supported by: Project UID/EQU/00511/2013-LEPABE, by the  
440 FCT/MEC with national funds and when applicable co-funded by FEDER in the scope of the  
441 P2020 Partnership Agreement; Project NORTE-07-0124-FEDER-000025 - RL2\_  
442 Environment&Health, by FEDER funds through Programa Operacional Factores de  
443 Competitividade – COMPETE, by the Programa Operacional do Norte (ON2) program and by  
444 national funds through FCT - Fundação para a Ciência e a Tecnologia; Project “DNA mimics”

445 PIC/IC/82815/2007; PhD Fellowship [SFRH/BD/82663/ 2011]; and Postdoctoral Fellowship  
446 [SFRH/BPD/74480/2010].  
447 The authors would like to thank to M. Fenice and A. Steinbüchel for kindly providing the *Delftia*  
448 *tsuruhatensis* BM90 and *Achromobacter xylosoxidans* B3 strains, respectively.

449  
450

## 451 **References**

- 452 Al-Bakri AG, Gilbert P, Allison DG. 2005. Influence of gentamicin and tobramycin on binary  
453 biofilm formation by co-cultures of *Burkholderia cepacia* and *Pseudomonas aeruginosa*. J Basic  
454 Microbiol. 45:392-396.
- 455 Almeida C, Azevedo NF, Bento JC, Cerca N, Ramos H, Vieira MJ, Keevil CW. 2013. Rapid  
456 detection of urinary tract infections caused by *Proteus* spp. using PNA-FISH. Eur J Clin  
457 Microbiol. 32:781-786.
- 458 Armbruster CE, Smith SN, Yep A, Mobley HL. 2014. Increased incidence of urolithiasis and  
459 bacteremia during *Proteus mirabilis* and *Providencia stuartii* coinfection due to synergistic  
460 induction of urease activity. J Infect Dis. 209:1524-1532.
- 461 Azevedo AS, Almeida C, Melo LF, Azevedo NF. 2014. Interaction between atypical  
462 microorganisms and *E. coli* in catheter-associated urinary tract biofilms. Biofouling. 30:893-902.
- 463 Azevedo AS, Almeida C, Pereira B, Madureira P, Wengel J, Azevedo NF. 2015. Detection and  
464 discrimination of biofilm populations using locked nucleic acid/2'-O-methyl-RNA fluorescence  
465 *in situ* hybridization (LNA/2'OMe-FISH). Biochemi Eng J. 104:64-73.
- 466 Azevedo NF, Pacheco AP, Keevil CW, Vieira MJ. 2006. Adhesion of water stressed *Helicobacter*  
467 *pylori* to abiotic surfaces. J Appl Microbiol. 101:718-724.
- 468 Baldan R, Cigana C, Testa F, Bianconi I, De Simone M, Pellin D, Di Serio C, Bragonzi A, Cirillo  
469 DM. 2014. Adaptation of *Pseudomonas aeruginosa* in Cystic Fibrosis airways influences  
470 virulence of *Staphylococcus aureus in vitro* and murine models of co-infection. PLoS One.  
471 9:e89614.
- 472 Brooks T, Keevil CW. 1997. A simple artificial urine for the growth of urinary pathogens. Lett  
473 Appl Microbiol. 24:203-206.
- 474 Broszat M, Grohmann E. 2014. Antibiofilm Agents. Springer Berlin Heidelberg. Chpter 5,  
475 Horizontal Gene Transfer in Planktonic and Biofilm Modes; p. 67-95.
- 476 Burmolle M, Webb JS, Rao D, Hansen LH, Sorensen SJ, Kjelleberg S. 2006. Enhanced biofilm  
477 formation and increased resistance to antimicrobial agents and bacterial invasion are caused by  
478 synergistic interactions in multispecies biofilms. Appl Environ Microbiol. 72:3916-3923.
- 479 Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. 1999. The Calgary Biofilm Device:  
480 new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin  
481 Microbiol. 37:1771-1776.
- 482 Cerqueira L, Oliveira JA, Nicolau A, Azevedo NF, Vieira MJ. 2013. Biofilm formation with  
483 mixed cultures of *Pseudomonas aeruginosa/Escherichia coli* on silicone using artificial urine to  
484 mimic urinary catheters. Biofouling. 29:829-840.
- 485 Dellimore KH, Helyer AR, Franklin SE. 2013. A scoping review of important urinary catheter  
486 induced complications. J Mater Sci Mater Med. 24:1825-1835.
- 487 Duetz WA. 2007. Microtiter plates as mini-bioreactors: miniaturization of fermentation methods.  
488 Trends Microbiol. 15:469-475.
- 489 Elias S, Banin E. 2012. Multi-species biofilms: living with friendly neighbors. FEMS Microbiol  
490 Rev. 36:990-1004.

491 Fenice M, Gallo A, Juarez-Jimenez B, Gonzalez-Lopez J. 2007. Screening for extracellular  
492 enzyme activities by bacteria isolated from samples collected in the Tyrrhenian Sea. *Ann*  
493 *Microbiol.* 57:93-99.

494 Foster KR. 2011. The Secret Social Lives of Microorganisms. *Microbe.* 6:183-186.

495 Frank DN, Wilson SS, St Amand AL, Pace NR. 2009. Culture-independent microbiological  
496 analysis of foley urinary catheter biofilms. *PLoS One.* 4:e7811.

497 Ghigo JM. 2001. Natural conjugative plasmids induce bacterial biofilm development. *Nature.*  
498 412:442-445.

499 Gould I, van der Meer J, Ciofu O, Høiby N. 2008. Antibiotic Policies: Fighting Resistance.  
500 Springer US. *Cystic Fibrosis-Coping with Resistance*; p. 149-174.

501 Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. 2010. Antibiotic resistance of bacterial  
502 biofilms. *Int J Antimicrob Agents.* 35:322-332.

503 Hola V, Ruzicka F, Horka M. 2010. Microbial diversity in biofilm infections of the urinary tract  
504 with the use of sonication techniques. *FEMS Immunol MedMicrobiol.* 59:525-528.

505 Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, Saint S, Schaeffer AJ,  
506 Tambayh PA, Tenke P, et al. 2010. Diagnosis, prevention, and treatment of catheter-associated  
507 urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the  
508 Infectious Diseases Society of America. *Clin Infect Dis.* 50:625-663.

509 Jacobsen SM, Stickler DJ, Mobley HL, Shirliff ME. 2008. Complicated catheter-associated  
510 urinary tract infections due to *Escherichia coli* and *Proteus mirabilis*. *Clin Microbiol Rev.* 21:26-  
511 59.

512 Kara D, Luppens SB, Cate JM. 2006. Differences between single- and dual-species biofilms of  
513 *Streptococcus mutans* and *Veillonella parvula* in growth, acidogenicity and susceptibility to  
514 chlorhexidine. *Eur J Oral Sci.* 114:58-63.

515 Kline KA, Schwartz DJ, Gilbert NM, Hultgren SJ, Lewis AL. 2012. Immune modulation by group  
516 B *Streptococcus* influences host susceptibility to urinary tract infection by uropathogenic  
517 *Escherichia coli*. *Infect Immun.* 80:4186-4194.

518 Klinth JE, Castelain M, Uhlin BE, Axner O. 2012. The influence of pH on the specific adhesion  
519 of P piliated *Escherichia coli*. *PLoS One.* 7:e38548.

520 Kohanski MA, Dwyer DJ, Collins JJ. 2010. How antibiotics kill bacteria: from targets to  
521 networks. *Nat Rev Microbiol.* 8:423-435.

522 Kostaki M, Chorianopoulos N, Braxou E, Nychas GJ, Giaouris E. 2012. Differential biofilm  
523 formation and chemical disinfection resistance of sessile cells of *Listeria monocytogenes* strains  
524 under monospecies and dual-species (with *Salmonella enterica*) conditions. *Appl Environ*  
525 *Microbiol.* 78:2586-2595.

526 Kumar S, Wittmann C, Heinzle E. 2004. Review: Minibioreactors. *Biotechnol Lett.* 26:1-10.

527 Lawrence EL, Turner IG. 2005. Materials for urinary catheters: a review of their history and  
528 development in the UK. *Med Eng Phys.* 27:443-453.

529 Lee KW, Periasamy S, Mukherjee M, Xie C, Kjelleberg S, Rice SA. 2014. Biofilm development  
530 and enhanced stress resistance of a model, mixed-species community biofilm. *ISME J.* 8:894-  
531 907.

532 Lenski RE, Rose MR, Simpson SC, Tadler SC. 1991. Long-Term Experimental Evolution in  
533 *Escherichia coli*. I. Adaptation and Divergence During 2,000 Generations. *Am Nat.* 138:1315-  
534 1341.

535 Leriche V, Briandet R, Carpentier B. 2003. Ecology of mixed biofilms subjected daily to a  
536 chlorinated alkaline solution: spatial distribution of bacterial species suggests a protective effect  
537 of one species to another. *Environ Microbiol.* 5:64-71.

538 Lopes SP, Azevedo NF, Pereira MO. 2014. Emergent bacteria in cystic fibrosis: *in vitro* biofilm  
539 formation and resilience under variable oxygen conditions. *Biomed Res Int.* 2014:678301.

540 Lopes SP, Azevedo NF, Pereira MO. 2015. Microbiome in cystic fibrosis: Shaping polymicrobial  
541 interactions for advances in antibiotic therapy. *Crit Rev Microbiol.* 41:353-365.

542 Lopes SP, Ceri H, Azevedo NF, Pereira MO. 2012. Antibiotic resistance of mixed biofilms in  
543 cystic fibrosis: impact of emerging microorganisms on treatment of infection. *Int J Antimicrob*  
544 *Agents.* 40:260-263.

545 Lyczak JB, Cannon CL, Pier GB. 2002. Lung infections associated with cystic fibrosis. *Clin*  
546 *Microbiol Rev.* 15:194-222.

547 May T, Ito A, Okabe S. 2009. Induction of multidrug resistance mechanism in *Escherichia coli*  
548 biofilms by interplay between tetracycline and ampicillin resistance genes. *Antimicrob Agents*  
549 *Chemother.* 53:4628-4639.

550 Nicolle LE. 2005. Catheter-related urinary tract infection. *Drugs Aging.* 22:627-639.

551 Niveditha S, Pramodhini S, Umadevi S, Kumar S, Stephen S. 2012. The isolation and the biofilm  
552 formation of uropathogens in the patients with catheter associated urinary tract infections (UTIs).  
553 *J Clin Diagn Res.* 6:1478-1482.

554 Perlin MH, Clark DR, McKenzie C, Patel H, Jackson N, Kormanik C, Powell C, Bajorek A,  
555 Myers DA, Dugatkin LA, et al. 2009. Protection of Salmonella by ampicillin-resistant  
556 *Escherichia coli* in the presence of otherwise lethal drug concentrations. *Proc Biol Sci.* 276:3759-  
557 3768.

558 Raffi HS, Bates JM, Flournoy DJ, Kumar S. 2012. Tamm-Horsfall protein facilitates catheter  
559 associated urinary tract infection. *BMC Res Notes.* 5:532.

560 Reinecke F, Groth T, Heise KP, Joentgen W, Muller N, Steinbuchel A. 2000. Isolation and  
561 characterization of an *Achromobacter xylosoxidans* strain B3 and other bacteria capable to  
562 degrade the synthetic chelating agent iminodisuccinate. *FEMS Microbiol Lett.* 188:41-46.

563 Ronald A. 2002. The etiology of urinary tract infection: traditional and emerging pathogens. *Am*  
564 *J Med.* 113:14S-19S.

565 Savage VJ, Chopra I, O'Neill AJ. 2013. *Staphylococcus aureus* biofilms promote horizontal  
566 transfer of antibiotic resistance. *Antimicrob Agents Chemother.* 57:1968-1970.

567 Siener R, Jahnen A, Hesse A. 2004. Influence of a mineral water rich in calcium, magnesium and  
568 bicarbonate on urine composition and the risk of calcium oxalate crystallization. *Eur J Clin Nutr.*  
569 58:270-276.

570 Simoes M, Simoes LC, Vieira MJ. 2009. Species association increases biofilm resistance to  
571 chemical and mechanical treatments. *Water Res.* 43:229-237.

572 Spadafino JT, Cohen B, Liu J, Larson E. 2014. Temporal trends and risk factors for extended-  
573 spectrum beta-lactamase-producing *Escherichia coli* in adults with catheter-associated urinary  
574 tract infections. *Antimicrob Resist Infect Control.* 3:39.

575 Steinman MA, Gonzales R, Linder JA, Landefeld CS. 2003. Changing use of antibiotics in  
576 community-based outpatient practice, 1991-1999. *Ann Intern Med.* 138:525-533.

577 Stickler DJ. 2008. Bacterial biofilms in patients with indwelling urinary catheters. *Nat Clin Pract*  
578 *Urol.* 5:598-608.


579 West SA, Griffin AS, Gardner A, Diggle SP. 2006. Social evolution theory for microorganisms.  
580 *Nat Rev Micro.* 4:597-607.

581 Wu S, Li X, Gunawardana M, Maguire K, Guerrero-Given D, Schaudinn C, Wang C, Baum MM,  
582 Webster P. 2014. Beta-lactam antibiotics stimulate biofilm formation in non-typeable  
583 haemophilus influenzae by up-regulating carbohydrate metabolism. *PLoS One.* 9:e99204.

584 Yurtsev EA, Chao HX, Datta MS, Artemova T, Gore J. 2013. Bacterial cheating drives the  
585 population dynamics of cooperative antibiotic resistance plasmids. *Mol Syst Biol.* 9:683.


586 Zhanell GG, Karlowsky JA, Harding GK, Carrie A, Mazzulli T, Low DE, Hoban DJ. 2000. A  
 587 Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the  
 588 activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and  
 589 ciprofloxacin. The Canadian Urinary Isolate Study Group. *Antimicrob Agents Chemother.*  
 590 44:1089-1092.

591




592

593 Figure 1. Single and dual-species biofilm growth on silicone material.  
 594 Notes: The three species were individually cultured or co-cultured at 37°C, on silicone coupons,  
 595 under static conditions. Two independent experiments were performed for each condition. Error bars  
 596 represent the SD. (A) Representation of the relative fitness of *E. coli* when co-cultured with the  
 597 uncommon species (*D. tsuruhatensis* and *A. xylosoxidans*). The dashed line represents a relative  
 598 fitness of 1, which means that the species are equally fit. The asterisk (\*) placed over the bars  
 599 indicates a statistically significant difference between the relative fitness of *E. coli* in dual-species  
 600 biofilms and 1 ( $p < 0.05$ ). (B) CLSM images of (I) *E. coli* 10<sup>5</sup> CFU ml<sup>-1</sup>/*D. tsuruhatensis* 10<sup>5</sup> CFU ml<sup>-1</sup>  
 601 and (II) *E. coli* 10<sup>5</sup> CFU ml<sup>-1</sup>/*A. xylosoxidans* 10<sup>5</sup> CFU ml<sup>-1</sup>, distinguishing each bacterium in two  
 602 different fluorescence channels and the superposition of the two fields. (C) CLSM showing the spatial  
 603 organization of the biofilm of (I) *E. coli* 10<sup>5</sup> CFU ml<sup>-1</sup>/*D. tsuruhatensis* 10<sup>5</sup> CFU ml<sup>-1</sup> and (II) *E. coli* 10<sup>5</sup>  
 604 CFU ml<sup>-1</sup>/*A. xylosoxidans* 10<sup>5</sup> CFU ml<sup>-1</sup> 192 h dual-species biofilms. The bottom images represent  
 605 the transverse planes.  
 606




607  
608  
609  
610  
611  
612  
613


Figure 2. Relative bacterial composition of the dual-species biofilms after antibiotic exposure. Notes: For each antibiotic, the *E. coli*/*D. tsuruhatensis* (A) and *E. coli*/*A. xylosoxidans* (B) 48 h dual-species biofilms were exposed to three different concentrations below the MBEC; then, the CFU counts were determined after exposure for 24 h. An initial inoculum concentration of 10<sup>5</sup> CFU ml<sup>-1</sup> was used for these experiments. Two independent experiments were performed for each condition.




614  
 615 Figure 3. Effect of a lower *D. tsuruhatensis* or *A. xylosoxidans* initial inoculum concentration (10<sup>2</sup> CFU  
 616 ml<sup>-1</sup>) on the *E. coli* population after antibiotic exposure. Notes: For each antibiotic, the *E. coli*/*D.*  
 617 *tsuruhatensis* (A) and *E. coli*/*A. xylosoxidans* (B) 48 h dual-species biofilms were exposed to  
 618 three different concentrations below the MBEC, then the CFU counts were determined after  
 619 exposure for 24 h. An *E. coli* initial inoculum concentration of 10<sup>5</sup> CFU ml<sup>-1</sup> was used for these  
 620 experiments. Two independent experiments were performed for each condition.  
 621



622 Figure 4. Effect of a lower *E. coli* initial inoculum concentration ( $10^2$  CFU ml<sup>-1</sup>) on the relative  
 623 bacterial composition of the dual-species biofilms after exposure to ampicillin and  
 624 amoxicillin/clavulanic acid. Notes: For each antibiotic, the *E. coli*/*D. tsuruhatensis* (A) and *E. coli*/*A.*  
 625 *xylosoxidans* (B) 48 h dual-species biofilms were exposed to three different concentrations below the  
 626 MBEC, then, the CFU counts were determined after exposure for 24 h. An initial inoculum  
 627 concentration of  $10^5$  CFU ml<sup>-1</sup> for *D. tsuruhatensis* and *A. xylosoxidans* was used for these  
 628 experiments. Two independent experiments  
 629 were performed for each condition.  
 630  
 631



632 Figure 5. Spatial localization and structure of dual-species biofilms exposed to ampicillin.  
 633 Notes: CLSM images showing the spatial organization of the biofilm of (I) *E. coli*  $10^5$  CFU ml<sup>-1</sup>/*D.*  
 634 *tsuruhatensis*  $10^5$  CFU ml<sup>-1</sup> before the ampicillin exposure; and (II) *E. coli*  $10^5$  CFU ml<sup>-1</sup>/  
 635 *D. tsuruhatensis*  $10^5$  CFU ml<sup>-1</sup>, (III) *E. coli*  $10^5$  CFU ml<sup>-1</sup>/*D. tsuruhatensis*  $10^2$  CFU ml<sup>-1</sup>, and (IV) *E.*  
 636 *coli*  $10^2$  CFU ml<sup>-1</sup>/*D. tsuruhatensis*  $10^5$  CFU ml<sup>-1</sup> after ampicillin treatment; (V) *E. coli*  
 637  $10^5$  CFU ml<sup>-1</sup>/*A. xylosoxidans*  $10^5$  CFU ml<sup>-1</sup> before the ampicillin exposure; and (VI) *E. coli*  $10^5$  CFU  
 638 ml<sup>-1</sup>/*A. xylosoxidans*  $10^5$  CFU ml<sup>-1</sup>, (VII) *E. coli*  $10^5$  CFU ml<sup>-1</sup>/*A. xylosoxidans*  $10^2$  CFU ml<sup>-1</sup>,  
 639 and (VIII) *E. coli*  $10^2$  CFU ml<sup>-1</sup>/*A. xylosoxidans*  $10^5$  CFU ml<sup>-1</sup> after ampicillin treatment. The bottom  
 640 and side images of each panel represent the transverse planes.  
 641



643  
 644  
 645  
 646  
 647  
 648  
 649  
 650  
 651  
 652  
 653  
 654  
 655  
 656  
 657

Figure 6. Schematic representation of the hypothesis proposed in the present work to explain the predominance of a certain species when a dual-species biofilm is exposed to antibiotics. Notes: After antibiotic exposure, (A) typically the species more resistant survives and dominates the microbial consortia; (B) however, the opposite can occur, and, the more susceptible species resists and dominates. Some hypothesis to explain that observation include: (1) transfer of genetic material from the resistant species to the susceptible species; (2) induction of a different physiological state in the susceptible species due to antibiotic uptake; (3) degradation of the antibiotic in the biofilm matrix, through the action of the enzymes produced by the resistant species.

Table 1. MBEC values for *E. coli*, *D. tsuruhatensis* and *A. xylosoxidans* single- and dual-species biofilms, exposed to four antibiotics.

	Antibiotic (mg l <sup>-1</sup> )			
	Ciprofloxacin	Ampicillin	Gentamicin	Amoxicillin/clavulanic acid*
	MBEC	MBEC	MBEC	MBEC
<i>E. coli</i>	256	128	2	64/9.15
<i>D. tsuruhatensis</i>	256	>1,024	256	>1,024/146.29
<i>A. xylosoxidans</i>	256	>1,024	32	>1,024/146.29
<i>E. coli/D. tsuruhatensis</i>	0.50	>1,024	64	>1,024/146.29
<i>E. coli/A. xylosoxidans</i>	256	>1,024	64	>1,024/146.29

\*Ratio 1/7 used in clinical treatments; MBEC, minimum biofilm eradication concentration. Note: An initial inoculum concentration of 10<sup>5</sup> CFU ml<sup>-1</sup> was used for these experiments.

658  
 659  
 660  
 661  
 662  
 663

Table 2. Effect of a low *D. tsuruhatensis* or *A. xylosoxidans* initial inoculum concentration (10<sup>2</sup> CFU ml<sup>-1</sup>) on the *in vitro* susceptibility of the dual-species biofilms to four antibiotics.

	Antibiotic (mg l <sup>-1</sup> )			
	Ciprofloxacin	Ampicillin	Gentamicin	Amoxicillin/clavulanic acid*
	MBEC	MBEC	MBEC	MBEC
<i>E. coli</i> 10 <sup>5</sup> CFU ml <sup>-1</sup> / <i>D. tsuruhatensis</i> 10 <sup>2</sup> CFU ml <sup>-1</sup>	0.5	512	16	512
<i>E. coli</i> 10 <sup>5</sup> CFU ml <sup>-1</sup> / <i>A. xylosoxidans</i> 10 <sup>2</sup> CFU ml <sup>-1</sup>	128	256	16	128

\*Ratio 1/7 used in clinical treatments; MBEC, minimum biofilm eradication concentration.

664